Design Therapeutics, Inc. DSGN
Design Therapeutics, Inc. (Nasdaq: DSGN) is an ophthalmology drug developer. Its lead program, DT-168, is in Phase 2 for Fuchs endothelial corneal dystrophy (FECD). Its next catalyst on record is DT-216P2: Update on registrational plans (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: DT-216P2 — Update on registrational plans (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DT-168 (eye drop, GeneTAC) | Fuchs endothelial corneal dystrophy | small molecule | Phase 2 |
| DT-216P2 (GeneTAC), RESTORE-FA Phase 1/2 | Friedreich ataxia | small molecule | Phase 1 |
| DT-818 (GeneTAC) | myotonic dystrophy type 1 | small molecule | Phase 1 |
| HD GeneTAC candidates | Huntington's disease | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.